Ilinpru Combi

Metformin Hydrochloride and Linagliptin, the active ingredients in Ilinpru Combi, are a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adults by improving blood glucose control. GNH USA supplies Ilinpru Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilinpru Combi combines metformin and linagliptin to manage hyperglycemia in type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycemic control when used with diet and exercise. Inadequate control with metformin alone: provides additional glucose‑lowering effect. Patients intolerant to sulfonylureas: offers an alternative mechanism of action. Combination therapy: synergistic effect with other antidiabetic agents. Adjunct to lifestyle modification: supports overall metabolic management.

Ilinpru Combi may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Dizziness: transient episodes, especially after dose initiation. - Upper respiratory symptoms: mild cough or sore throat. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before prescribing Ilinpru Combi, clinicians should consider several safety aspects.

Renal function monitoring: assess creatinine clearance before initiation and periodically. Hepatic function assessment: avoid use in patients with severe hepatic impairment. Elderly patients: start at lower doses and monitor for hypoglycemia. Concurrent hypoglycemic agents: adjust doses to reduce risk of low blood sugar. Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. Store at room temperature: keep in the original container, protect from moisture and heat.

Ilinpru Combi can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; discontinue metformin temporarily. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase linagliptin exposure. - Rifampicin: reduces linagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Sulfonylureas: heightened risk of hypoglycemia; dose adjustment may be needed. - Diuretics: may affect renal clearance of metformin. - NSAIDs: can impair renal function, increasing metformin accumulation. - ACE inhibitors/ARBs: monitor renal function and potassium levels.